10.1182/blood-2017-05-780049 - Five-year results of brentuximab vedo...

This document has been corrected

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

10.1182/blood-2017-05-780049

Published Online: 2017-12-21

Journal: Blood•Publisher: American Society of Hematology

Authors: Andrei Shustov•Barbara Pro•Dana A. Kennedy•Dirk Huebner•Jeffrey Matous•Joseph D. Rosenblatt•Joseph M. Connors•Juan M. Pinelli•Keenan Fenton•Michelle Fanale•Nancy L. Bartlett•Pauline Brice•Radhakrishnan Ramchandren•Ranjana Advani•Tim Illidge

This document has been corrected

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

10.1182/blood-2017-05-780049

Published Online: 2017-12-21

Journal: Blood

NOW

2018-07-26•Erratum

Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709-2717.

10.1182/blood-2018-05-853192

* information provided by CrossRef

2018-07-26•Erratum

10.1182/blood-2018-05-853192

* information provided by CrossRef

2017-12-21•Published

2018-07-26•Erratum

Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709-2717.

10.1182/blood-2018-05-853192

* information provided by CrossRef

This document has been corrected

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

10.1182/blood-2017-05-780049

Published Online: 2017-12-21

Journal: Blood•Publisher: American Society of Hematology